New study aims to spare thousands of breast cancer patients from unnecessary chemo
NCT ID NCT07379918
First seen Feb 02, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study is looking at a test called EndoPredict that helps doctors figure out the risk of breast cancer coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the test can accurately identify who can safely skip chemotherapy and just take hormone therapy. About 1,000 participants will be followed for 10 years to track cancer recurrence and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint-Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.